



Anika Therapeutics Postpones Release of Third-Quarter 2012 Financial Results to October 30

Anika Therapeutics Postpones Release of Third-Quarter 2012 Financial Results to October 30 BEDFORD, Mass. -- (BUSINESS WIRE)--Oct. 29, 2012-- [Anika Therapeutics, Inc.](#) (Nasdaq: ANIK) today announced that, due to the weather-related emergency on the East Coast, the company plans a one-day delay in the release of its third-quarter 2012 financial results. The company now plans to release its results after 4:00 p.m. ET on Tuesday, October 30, 2012. The company plans to hold a conference call the next day, Wednesday, October 31, at 9:00 a.m. ET to discuss its financial results, business highlights and outlook. In addition, the company will answer questions concerning business and financial developments and trends, and other business and financial matters affecting the company, some of the responses to which may contain information that has not been previously disclosed.

To listen to the conference call, dial 866-730-5767 (international callers dial 857-350-1591) and use the passcode 37817443. In addition, the call will be available through a live audio webcast in the "[Investor Relations](#)" section of Anika's website, [www.anikatherapeutics.com](#). An accompanying slide presentation also can be accessed via the Anika Therapeutics website. The call will be archived and accessible on the same website shortly after its conclusion.

The webcast also is being distributed through the Thomson StreetEvents Network. Individual investors can listen to the call at [www.earnings.com](#), Thomson's individual investor portal, powered by StreetEvents. Institutional investors can access the call via Thomson StreetEvents ([www.streetevents.com](#)), a password-protected event management site.

About Anika Therapeutics, Inc.

Headquartered in Bedford, Mass., [Anika Therapeutics, Inc.](#) develops, manufactures and commercializes therapeutic products for tissue protection, healing, and repair. These products are based on hyaluronic acid (HA), a naturally occurring, biocompatible polymer found throughout the body. Anika's products range from orthopedic/joint health solutions led by Orthovisc®, a treatment for osteoarthritis of the knee; to surgical aids in the ophthalmic and anti-adhesion fields. The company also offers aesthetic dermal fillers for the correction of facial wrinkles. Anika's Italian subsidiary, Anika Therapeutics, S.r.l, provides complementary HA products in orthopedic/joint health and anti-adhesion, as well as therapeutics in new areas such as advanced wound treatment and ear, nose and throat care. Its regenerative tissue technology advances Anika's vision to offer therapeutic products that go beyond pain relief to protect and restore damaged tissue.

Source: Anika Therapeutics, Inc.

Anika Therapeutics, Inc.
Charles H. Sherwood, Ph.D., 781-457-9000
CEO
or
Kevin W. Quinlan, 781-457-9000
CFO

<https://ir.anika.com/Anika-Therapeutics-Postpones-Release-of-Third-Quarter-2012-Financial-Results-to-October-30>